Compare Mondaycom Ltd (MNDY) vs TG Therapeutics Inc (TGTX) Price & Performance

Monday.com (MNDY) trades at $88.96, up 6.53% in the last session, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company demonstrates robust revenue growth reaching $1.23 billion in 2025 with impressive 88.74% gross margins, though valuation multiples remain elevated with a P/E of 37.69. Recent news highlights the company's AI initiatives at its Elevate '26 conference and inclusion in multiple growth stock lists.

The outlook remains positive with Wall Street consensus at $108.64 target price and 65% buy ratings, though risks include competitive pressure from Meta's enterprise push and elevated valuation multiples. Earnings momentum continues with three consecutive quarterly beats, but investors should monitor the upcoming Q3 2026 results against $1.37 EPS expectations for continued validation of growth trajectory.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.